1 Further, in mice bearing
orthotopic 22Rv1 human prostate tumors, we did not find
2 tively inhibits the growth of an aggressive,
orthotopic 4T1 tumor model in vivo than free DOX and GEM
3 All tracers rapidly accumulated in
orthotopic 4T1luc tumors, allowing for the successful PE
4 icacy study of beta-lap-dC3 micelles against
orthotopic A549 NSCLC xenograft-bearing mice showed sign
5 Moreover, metastatic progression of Myc-CaP
orthotopic allografts is restricted by SPARCL1 in the tu
6 rmore, administration of SPHK1 inhibitors to
orthotopic AML patient-derived xenografts reduced tumor
7 rostate cancer cells to repopulate tumors in
orthotopic and heterotopic tissues.
8 nd underexpressing PHD3 were investigated in
orthotopic and heterotopic tumor models.
9 gnificantly inhibits tumor growth in both an
orthotopic and the PKT mouse model of PDAC.
10 umour cell growth in xenograft and syngeneic
orthotopic animal models, and induces growth inhibition
11 R and its target genes in PCa cell lines and
orthotopic animal tumours.
12 In the
orthotopic BALB/cJ model, extramedullary hematopoiesis o
13 decreased the incidence of MIBCs in a murine
orthotopic bladder cancer model and decreased the expres
14 inhibited cell migration in vitro and in an
orthotopic brain tumor model, in accordance with the kno
15 asmid DNA loaded in DNA-CN in two aggressive
orthotopic brain tumor models in rats.
16 pidly penetrate healthy brain parenchyma and
orthotopic brain tumor tissues in rats.
17 uantum dots are intravenously delivered into
orthotopic breast and pancreas tumors in mice by using t
18 Tracers were tested in an
orthotopic breast cancer model using 4T1luc-bearing syng
19 mal growth-factor receptor aptamer inhibited
orthotopic breast cancer models.
20 Animal studies using mice carrying
orthotopic breast MDA-MB-231 tumors showed that the cycl
21 or models and drug-induced alterations in an
orthotopic breast tumor model.
22 to generate in vivo mouse models containing
orthotopic breast tumors for in vivo SPECT/MRI and biodi
23 t treatment of immune competent mice bearing
orthotopic breast tumors with anti-mouse CD47 antibodies
24 PET/CT imaging in an
orthotopic Capan-2 xenograft model--which secretes large
25 Apc(Min/+) mice and NSG mice with
orthotopic cecal tumors were given vehicle (controls), P
26 es sustained suppression of tumorigenesis in
orthotopic circulating tumour cell-derived tumour models
27 In this study, using an
orthotopic colorectal cancer (CRC) model, we found that
28 RT followed by IGF1R neutralization in
orthotopic colorectal cancer models reduced the number o
29 In a mouse
orthotopic colorectal cancer xenograft model, expression
30 promotes lymphangiogenesis and metastasis by
orthotopic colorectal tumors in mice and reduces lymphat
31 arriers in human tumor tissues and mice with
orthotopic colorectal tumors.
32 Orthotopic corneal transplantation was performed in heme
33 Mice bearing
orthotopic CT-2A or GL261 gliomas received POL5551 and/o
34 Through the
orthotopic engraftment of colon organoids we describe a
35 ized leukemia and lymphoma PDXs that undergo
orthotopic engraftment, called the Public Repository of
36 olony formation, as well as tumorigenesis in
orthotopic engraftments in mice.
37 er esophageal xenografts, and nude rats with
orthotopic esophageal cancers in four study groups of si
38 P < .001) of rat
orthotopic esophageal cancers.
39 square millimeter +/- 0.11 P < .001) of rat
orthotopic esophageal cancers.
40 hance local chemotherapy in a rat model with
orthotopic esophageal squamous cancers.
41 radable nanocarriers, and in vivo testing in
orthotopic experimental gliomas.
42 delivered from the systemic circulation into
orthotopic F98 gliomas using MRgFUS, where they elicited
43 In two
orthotopic GB xenograft mouse models, intracranial admin
44 al administration of CBL0137 to mice bearing
orthotopic GBM prolonged their survival.
45 lood-brain/blood-tumor barriers (BBB/BTB) in
orthotopic GBM xenografts and selectively disseminated t
46 nct patient-derived GSC lines and visualized
orthotopic GBM xenografts in vivo after conjugation with
47 tion, and prolonged survival in mice bearing
orthotopic GBM xenografts.
48 and tumor control in a high-grade transgenic
orthotopic glioblastoma model.
49 construct (chNKG2D) in fully immunocompetent
orthotopic glioblastoma mouse models.
50 In an
orthotopic glioblastoma xenograft model expressing mutat
51 asanutlin resulted in synthetic lethality in
orthotopic glioblastoma xenograft models.
52 stablished solid and diffuse patient-derived
orthotopic glioblastoma xenografts 230- and 20-fold, res
53 Median survival time of rats bearing
orthotopic glioma was significantly enhanced when cispla
54 titumor effects in treatment-naive tumors in
orthotopic (
grafted and genetically engineered) models o
55 hepatic artery, in contrast to conventional
orthotopic HCC xenografts that receive both arterial and
56 In human xenograft models of subcutaneous or
orthotopic HCC, administration of the selective SND1 inh
57 This study evaluated whether minority
orthotopic heart transplant (OHT) recipients tend to be
58 lt (>/=18 years old) recipients of a primary
orthotopic heart transplant performed between 2000 and 2
59 lant malignancy is a major cause of death in
orthotopic heart transplant recipients.
60 for Organ Sharing) for all adults listed for
orthotopic heart transplantation (2000-2015) with a list
61 Left ventricular (LV) dysfunction after
orthotopic heart transplantation (OHT) is multifactorial
62 ading cause of morbidity and mortality after
orthotopic heart transplantation (OHT).
63 with the diagnosis of myocarditis listed for
orthotopic heart transplantation are younger, sicker, an
64 Of 45 941 adults listed for
orthotopic heart transplantation during this period, we
65 hanical circulatory support, and outcomes of
orthotopic heart transplantation of these patients.
66 th patients with heart failure or those with
orthotopic heart transplantation, serum levels and endot
67 om 101 patients with heart failure, LVAD, or
orthotopic heart transplantation.
68 Adults aged 18 to 64 receiving first-time
orthotopic heart transplants between July 2006 and Decem
69 ding cells in vitro and in a patient-derived
orthotopic hepatocellular carcinoma model in mice.
70 d the ability of LDL-DHA to reduce growth of
orthotopic hepatomas in rats.
71 Orthotopic hind-limb transplantations were performed in
72 contrast, as confirmed in three subtypes of
orthotopic human lung cancer xenografts (A549, H460, and
73 Treatment of
orthotopic human pancreatic cancer tumor-bearing NSG mic
74 in tumor progression was studied by using an
orthotopic human pancreatic cancer xenograft mouse model
75 two murine models of lung cancer, including
orthotopic human xenograft and Kras(LSL/G12D) mouse mode
76 administration of the MagMBs to mice bearing
orthotopic human xenograft BxPC-3 tumours yielded a 48.3
77 In this study we employed an
orthotopic immunocompetent model of lung adenocarcinoma
78 etabolites increase during progression in an
orthotopic immunocompetent model of lung cancer.
79 Orthotopic implant of CCA human cells in the liver of im
80 Using an
orthotopic implantation model in mice, which uniquely re
81 Our in vivo studies with
orthotopic implantation models demonstrated a robust inc
82 ne in pancreatic cancer cells in culture and
orthotopic implantation models.
83 Moreover,
orthotopic implantation of PR55alpha-depleted pancreatic
84 Orthotopic injection in vivo of FGFR1-silenced osteosarc
85 rts of female Balb/C mice received bilateral
orthotopic injections of syngeneic 67NR, 4T07, or 4T1cel
86 Tumor-xenografts derived from
orthotopic-
inoculation of MYB-overexpressing PC cells ex
87 into different brain regions receives highly
orthotopic input.
88 Results of an
orthotopic intraperitoneal model of metastatic ovarian c
89 Orthotopic kidney and heterotopic heart transplantation
90 In each group,
orthotopic kidney transplantation was performed after re
91 Results were confirmed in an
orthotopic liver cancer model.
92 of unknown cause, and one patient underwent
orthotopic liver retransplantation (re-OLT) procedure du
93 , benign biliary strictures (N = 112) due to
orthotopic liver transplant (n = 73), chronic pancreatit
94 He subsequently underwent an
orthotopic liver transplant for definitive treatment of
95 with liver disease clinically considered for
orthotopic liver transplant for different indications we
96 Even though auxiliary partial
orthotopic liver transplantation (APOLT) as a technique
97 lic disorders are common complications after
orthotopic liver transplantation (OLT) and may lead to i
98 mining of intraoperative hemodynamic data in
orthotopic liver transplantation (OLT) can aid in the pr
99 ve previously shown that patients listed for
orthotopic liver transplantation (OLT) in United Network
100 The impact of ethnicity on outcomes after
orthotopic liver transplantation (OLT) is unclear.
101 und (DUS) arterial abnormalities (DAA) after
orthotopic liver transplantation (OLT) often represent a
102 t antithymocyte globulin (RATG) induction in
orthotopic liver transplantation (OLT) with tacrolimus m
103 In the context of
orthotopic liver transplantation (OLT), renal dysfunctio
104 tant causes of morbidity and mortality after
orthotopic liver transplantation (OLT).
105 disease (ESLD) and that it increases during
orthotopic liver transplantation (OLT).
106 key obstacle to expanding the donor pool in
orthotopic liver transplantation (OLT).
107 (HCC) recurrence and overall survival after
orthotopic liver transplantation and to identify factors
108 s operation, making it a safe alternative to
orthotopic liver transplantation for patients with a wid
109 Orthotopic liver transplantation in the mouse is a power
110 Despite the efficacy of
orthotopic liver transplantation in the treatment of end
111 Setup of the
orthotopic liver transplantation model comprises three m
112 ations after OLT, the Cardiovascular Risk in
Orthotopic Liver Transplantation risk score, among a coh
113 ation has been proposed as an alternative to
orthotopic liver transplantation to treat metabolic live
114 Orthotopic liver transplantation was performed using ste
115 fy factors that predict HCC recurrence after
orthotopic liver transplantation.
116 s are refractory to drug therapy and require
orthotopic liver transplantation.
117 y kills hepatoma cells and reduces growth of
orthotopic liver tumors in rats.
118 s Slug-mediated lung cancer metastasis in an
orthotopic lung metastasis mouse model.
119 In an in vivo mouse
orthotopic lung transplant model of BOS, antagonism of t
120 histocompatibility complex-mismatched mouse
orthotopic lung transplant model, we investigated a cond
121 ine PGD models were studied: hilar clamp and
orthotopic lung transplantation after prolonged cold isc
122 Previous studies in a mouse model of
orthotopic lung transplantation suggested a requirement
123 space in human lung cancer specimens and in
orthotopic lung tumors generated by injection of a LH2-e
124 Orthotopic malignant gliomas were established in syngene
125 In addition, in mice bearing
orthotopic malignant gliomas, inhibition with bevacizuma
126 In
orthotopic mammary carcinoma models, ADCC enhancement wa
127 Using
orthotopic mammary fat pad model of breast cancer (MDAMB
128 We employed an
orthotopic metastatic mouse model in which the PDA cells
129 rant subpopulations and tumor propagation of
orthotopic MKN45/5FU xenografts.
130 h and promoted apoptosis of GBM tumors in an
orthotopic model and improved the overall survival of tu
131 umor models, with the longest survival in an
orthotopic model of aggressive brain cancer.
132 strate that penfluridol administration to an
orthotopic model of breast cancer suppressed tumor growt
133 roliferation, survival, and metastasis in an
orthotopic model of colon cancer in vivo Upon RSPO1 stim
134 nally, evaluating therapeutic efficacy in an
orthotopic model of glioblastoma highlights the need to
135 a GARP-specific mAb limited metastasis in an
orthotopic model of human breast cancer.
136 increase in per-tumor-cell uptake in a mouse
orthotopic model of human triple-negative breast cancer.
137 n vitro, as well as metastasis in an in vivo
orthotopic model of melanoma.
138 We report here a novel
orthotopic model of non-small cell lung cancer in rats,
139 -15 in Ras-driven tumor xenografts and in an
orthotopic model of pancreatic cancer delayed tumor deve
140 ated with survival following ADT, we used an
orthotopic model of Pten/Tp53 null prostate cancer.
141 tions using multiple tumor cell lines in the
orthotopic model suggested the involvement of a C3/C3 re
142 urvival of ovarian cancer-bearing mice in an
orthotopic model.
143 BBB passage and tumor accumulation in a GBM
orthotopic model.
144 fold relative to the same formulation in the
orthotopic model.
145 of VEGFR/Ang-2 could improve survival in two
orthotopic models of GBM, Gl261 and U87.
146 acy studies conducted in two different mouse
orthotopic models of glioblastoma illustrated how enhanc
147 reduces metastases, and prolongs survival in
orthotopic models of human pancreatic cancer.
148 this association in multiple immunocompetent
orthotopic models of lung cancer.
149 d restricts tumor growth in subcutaneous and
orthotopic models of the disease.
150 r cells and inhibited lung metastasis in two
orthotopic models, but had little or no effect on primar
151 In preclinical studies using
orthotopic models, NCL-1 and NCD-38 significantly reduce
152 or burden and metastasis in restraint stress
orthotopic models.
153 odin depletion reduced lung metastasis in an
orthotopic mouse breast cancer model.
154 suppresses tumor growth and metastasis in an
orthotopic mouse model of ATC.
155 In an
orthotopic mouse model of breast cancer, we have demonst
156 y reduced the tumor burden in a pre-clinical
orthotopic mouse model of cervical cancer by decreasing
157 In an
orthotopic mouse model of glioma, we found that Cic loss
158 eath of GIC and increase host survival in an
orthotopic mouse model of human glioma.
159 Using our in vivo
orthotopic mouse model of lung cancer metastases, we fou
160 vitro Administration of miR-6126 mimic in an
orthotopic mouse model of ovarian cancer elicited a rela
161 In an
orthotopic mouse model of ovarian cancer, delivery of mi
162 suppressed tumor growth and metastasis in an
orthotopic mouse model of pancreatic cancer.
163 of primary tumors and liver metastasis in an
orthotopic mouse model of PDAC (mPDAC).
164 Using an
orthotopic mouse model of pleural mesothelioma, we deter
165 We have used this
orthotopic mouse model to investigate the source of IL-1
166 In an
orthotopic mouse model, IKKepsilon-silenced PDAC exhibit
167 xenograft tumor growth and metastasis in an
orthotopic mouse model.
168 oroglutamine compared with the kidney in the
orthotopic mouse model.
169 metastatic osteosarcoma cells in vivo in an
orthotopic mouse model.
170 ongation following temozolomide treatment of
orthotopic mouse models in vivo Our data indicate that m
171 eoadjuvant TSL HT combination therapy in two
orthotopic mouse models of human breast cancer, MDA-MB-2
172 In
orthotopic mouse models of melanoma and pancreatic ducta
173 In immunocompetent
orthotopic mouse models of pancreatic cancer and melanom
174 effects of itraconazole and paclitaxel using
orthotopic mouse models with established EOC cells (SKOV
175 growth and cancer invasion in xenograft and
orthotopic mouse models, respectively.
176 on attenuates in vivo glioblastoma growth in
orthotopic mouse xenograft models and a transgenic gliob
177 2) and C-X-C chemokine receptor 4 (CXCR4) in
orthotopic murine CRC models, including SL4 and CT26.
178 n brain tissue slices and in vivo testing in
orthotopic murine malignant glioma revealed preserved na
179 constructed and successfully validated in an
orthotopic murine tumor model.
180 BTIC in human glioblastoma specimens and in
orthotopic murine xenografts of human BTIC implanted int
181 synergistically enhance tumor regression in
orthotopic NSCLC mouse model.
182 three-dimensional culture and in an in vivo
orthotopic nude mouse model of HNSCC through a novel tra
183 nced during premalignancy and (b) an in vivo
orthotopic nude rat lung cancer model to evaluate respon
184 ancer models for drug discovery are based on
orthotopic or subcutaneous tumours.
185 nto rats with syngeneic tumors and mice with
orthotopic or xenograft tumors.
186 Analysis of
orthotopic oral tumors generated by cells with reduced K
187 asis, which rely on in situ gene editing and
orthotopic organoid transplantation in mice without canc
188 enoma-carcinoma sequence in vivo by using an
orthotopic organoid transplantation model of human colon
189 of a novel bioengineered miR-34a prodrug in
orthotopic OS xenograft tumor mouse model.
190 Successful detection of
orthotopic ovarian tumors is achieved by in vivo NIR-II
191 ed state, used these cell lines to establish
orthotopic ovarian tumors, and found that inducible expr
192 nificantly enhanced survival of animals with
orthotopic PaCa and cured peritoneally disseminated PaCa
193 y and prolonged survival were noted in human
orthotopic pancreatic and non-small-cell lung xenograft
194 's anti-tumour efficacy was explored against
orthotopic pancreatic and ovarian cancer tumours.
195 cimens and NK transfer in NSG mice harboring
orthotopic pancreatic cancer xenografts, we assessed CSC
196 Orthotopic pancreatic transplants of ETV1-overexpressing
197 In vivo, MSN-UPA particles demonstrated
orthotopic pancreatic tumor specific accumulation compar
198 In addition, imaging of
orthotopic pancreatic tumors was performed using (64)Cu-
199 odels and suppresses metastatic escape in an
orthotopic pancreatic tumour model.
200 for the treatment of pancreatic cancer in an
orthotopic patient-derived xenograft model.
201 rence (RNAi) screening technology for use in
orthotopic patient-derived xenograft models, creating a
202 We report the development of
orthotopic patient-derived xenografts (PDXs) of HER2-exp
203 sease, here we develop a protocol to produce
orthotopic patient-derived xenografts at diagnosis, recu
204 mplete response in multiple rhabdomyosarcoma
orthotopic patient-derived xenografts tumours in vivo.
205 mens were received from 168 patients, and 67
orthotopic patient-derived xenografts were established f
206 In a KRAS-induced
orthotopic PDAC model, coadministration of iRGD enhanced
207 We also used a syngeneic
orthotopic PDAC mouse model to study tumor growth in the
208 urvival in both obesity-driven and syngeneic
orthotopic PDAC mouse models.
209 jection or intravenous biodistribution to an
orthotopic PDAC site.
210 GBMs using both in vitro assays and in vivo
orthotopic preclinical models.
211 otopic tumors, and increased metastasis from
orthotopic primaries and following tail vein injection w
212 camptothecin, in preclinical mouse models of
orthotopic primary triple-negative breast tumor xenograf
213 les carrying paclitaxel and rubone inhibited
orthotopic prostate tumor growth in nude mice, compared
214 /-27b on prostate cancer metastasis in vivo,
orthotopic prostate xenografts were established using ag
215 g widespread transgene expression throughout
orthotopic rat brain tumors in vivo following administra
216 cipients underwent bilateral nephrectomy and
orthotopic renal transplantation (day 0).
217 In vivo, after
orthotopic RENCA cell renal transplantation, pulmonary t
218 In vivo, using a clinically relevant
orthotopic resection model of primary glioblastoma and e
219 Thus, this
orthotopic retinoblastoma model offers a new and unique
220 body enabled delineation of subcutaneous and
orthotopic SCLC tumor xenografts as well as distant orga
221 prove the early posttransplant outcome after
orthotopic small bowel transplantation.
222 We treated mice bearing
orthotopic syngeneic (Gl261) GBMs or human (MGG8) GBM xe
223 An
orthotopic syngeneic mouse model resulted in tumours wit
224 Using an
orthotopic syngeneic mouse tumor model, we make the stri
225 In vivo, CFI-402257 reduced MM growth in an
orthotopic,
syngeneic model, when used as a single agent
226 In vivo, tumors were induced in an
orthotopic,
syngeneic mouse model of advanced stage EOC.
227 pical imaging agent, spatially resolving the
orthotopic tongue tumors in vivo.
228 Orthotopic trachea transplantations were performed betwe
229 ity and suppressed alveolar hemorrhage in an
orthotopic transplant model for up to 3 h after extubati
230 In a preclinical
orthotopic transplant model of human GBM, thermoradiothe
231 Finally, we apply the
orthotopic transplantation model to characterize the clo
232 ses metastasis in intracardial xenograft and
orthotopic transplantation models, and correlates with p
233 e tumor-suppressive function of PTPN23 in an
orthotopic transplantation mouse model.
234 essor genes in colon epithelial cells and by
orthotopic transplantation of Apc-edited colon organoids
235 Orthotopic transplantation of DeltaNp63alpha-expressing
236 hly efficient HCC invasion and metastasis by
orthotopic transplantation of liver cancer organoids pro
237 Orthotopic transplantation of patient-derived organoids
238 In a mouse model using
orthotopic transplantation of patient-derived pancreatic
239 phological alterations and tumorigenicity in
orthotopic transplants.
240 In vivo
orthotopic tumor experiments showed inhibition of growth
241 y to the PARP inhibitor rucaparib and slower
orthotopic tumor growth compared with Trp53(-/-) cells,
242 ion of both ADHFE1 and MYC strongly enhanced
orthotopic tumor growth in MCF7 cells.
243 man and mouse breast cancer cells, decreased
orthotopic tumor growth, reduced tumor angiogenesis and
244 Using two different syngeneic,
orthotopic tumor implant models of breast cancer, we dis
245 hydrogels were used to treat two aggressive
orthotopic tumor models in athymic nude mice: a human PC
246 Using an
orthotopic tumor xenograft model, we demonstrated that e
247 erapy-treated human desmoplastic cancers and
orthotopic tumor xenografts revealed that traditional ma
248 (G12D/+);Tgfbr2(flox/flox) (PKT) mice and in
orthotopic tumor xenografts.
249 C cell proliferation in vitro and suppressed
orthotopic tumorigenicity in vivo.
250 or an adenovirus encoding human VEGFC before
orthotopic tumors and metastases formed.
251 e ability of PGE2 to induce CSC expansion in
orthotopic tumors and to accelerate the formation of liv
252 tention of the DART nanoparticles within the
orthotopic tumors compared to non-targeted versions.
253 Furthermore, subcutaneous and
orthotopic tumors from both BC cell lines were successfu
254 (KPC) mice, as well as in C57BL/6 mice with
orthotopic tumors grown from FC1242 cells derived from K
255 in Gd concentration in both heterotopic and
orthotopic tumors using dynamic quantitative MRI.
256 e to mediate gene silencing in xenograft and
orthotopic tumors via i.v. injection or aerosol inhalati
257 Orthotopic tumors were clearly visible on the PET/MR ima
258 as sufficient to increase the growth rate of
orthotopic tumors with significant effects observed on t
259 ng cell abundance in vivo yielding increased
orthotopic tumors, and increased metastasis from orthoto
260 fts (A549, H460, and H520) in mice and in an
orthotopic VX2 tumor in rabbits.
261 Compared with
orthotopic xenograft assays, the novel biomaterial cultu
262 tive and specific metastasis detection in an
orthotopic xenograft breast cancer model expressing the
263 importance of this complex in vivo using an
orthotopic xenograft breast cancer model.
264 antly inhibits tumor growth in vivo using an
orthotopic xenograft breast mouse model.
265 in subcutaneous syngeneic mouse melanoma and
orthotopic xenograft lung cancer models.
266 survival of PEL bearing NOD-SCID mice in an
orthotopic xenograft model as compared with either agent
267 e of these patients was used to establish an
orthotopic xenograft model of glioblastoma.
268 mation and growth of metastatic tumors in an
orthotopic xenograft model of prostate cancer, by greatl
269 In an
orthotopic xenograft model, IL-35 promotes spontaneous p
270 e cell lines, and prolonged survival in both
orthotopic xenograft models and mouse models of primary
271 In
orthotopic xenograft models of pancreatic cancer, combin
272 OTCH3 activation in 12 of 24 patient-derived
orthotopic xenograft models, 2 of which exhibit activati
273 Notably, using
orthotopic xenograft models, we demonstrate that combina
274 rew faster than wild-type clones in s.c. and
orthotopic xenograft models.
275 oma stem cells (GSCs) using cell culture and
orthotopic xenograft models.
276 were explored using murine subcutaneous and
orthotopic xenograft models.
277 ib revealed in vivo antitumor efficacy in an
orthotopic xenograft mouse model of two NB cell lines an
278 This
orthotopic xenograft mouse model will enable clinically
279 ified elongation factors extends survival in
orthotopic xenograft mouse models, suggesting that targe
280 x43 immunoreactivity at areas of invasion in
orthotopic xenograft mouse models.
281 ith WT and F1174L activating mutation ALK in
orthotopic xenograft mouse models.
282 rug significantly reduced OS tumor growth in
orthotopic xenograft mouse models.
283 1 significantly inhibited tumor growth in an
orthotopic xenograft NB mouse model by inducing Chk2/p53
284 ivo by enhancing dox-induced apoptosis in an
orthotopic xenograft NB mouse model.
285 ited growth of cervical cancer cells derived
orthotopic xenograft tumors in athymic nude mice.
286 the DRD2 inhibitor haloperidol to mice with
orthotopic xenograft tumors reduced final tumor size and
287 morigenic potential in both subcutaneous and
orthotopic xenograft tumour models.
288 -negative breast cancer, and patient-derived
orthotopic xenografts (PDX) of human glioblastoma.
289 assess the density of glioma cells in murine
orthotopic xenografts models and human brain tumors, tis
290 py experiments involved treating established
orthotopic xenografts of an aggressive metastatic varian
291 Orthotopic xenografts of MKN45/5FU cells in the stomach
292 to the 5-FU dose, and in gastric submucosal
orthotopic xenografts of MKN45/5FU cells.
293 Patient-derived
orthotopic xenografts of paediatric GBM, DIPG and adult
294 Limiting-dilution
orthotopic xenografts of these BCSCs regenerated origina
295 Analyses of mouse
orthotopic xenografts revealed that ETV1 induced signifi
296 In human GSC-derived
orthotopic xenografts, EFNB2 knock-down blocked tumour i
297 a cell proliferation in vitro, as well as in
orthotopic xenografts.
298 ost survival compared with untreated GSCs in
orthotopic xenografts.
299 Orthotopic xenotransplantation studies revealed that con
300 Here, we developed an
orthotopic zebrafish model in which retinoblastoma invas